

REMARKS

Claims 1, 3, 5-13 and 40-42 were pending in the application. Claims 2-3 have been canceled and claims 1, 8, and 11 have been amended by the amendments presented herein. Support for the amendments to the claims can be found, for example, page 14 of the application as filed. No new matter has been added.

Rejection of Claims 1, 3, 6 and 40-42 Under 35 USC 112, First Paragraph

The Examiner has rejected claims 1, 3, 6 and 40-42 because, “***while being enabling for an antibody generated against [a] peptide of at least 6 amino acids***” (emphasis added) the Examiner believes that the specification “does not reasonably provide enablement for [an] antibody generated against a peptide of 3 amino acids.” Applicants respectfully traverse this rejection.

However, solely in the interest of expediting prosecution, and in no way acquiescing to the validity of the Examiner’s rejection, Applicants have amended claim 1 to indicate that the antibody is generated against a 6 amino acid peptide of SEQ ID NO:4.

Based on the foregoing, Applicants respectfully request reconsideration and withdrawal of the foregoing enablement rejection.

Conclusion

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: January 21, 2010

Respectfully submitted,

Electronic Signature: /Jonathan M. Sparks/
Jonathan M. Sparks, Ph.D.

Registration No.: 53,624
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 517-5543
Attorneys/Agents For Applicant